Xylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study
Nutzung von Xylazine-Teststreifen bei schwangeren und postpartalen Frauen mit Opioidkonsumstörung: eine Pilotstudie
Pregnancy · 2026-03 · 2 (2)
DOI: 10.1002/pmf2.70274 ↗Auf einen Blick
Bei 50 schwangeren und postpartalen Frauen war eine perinatale XTS-Intervention gut durchführbar und akzeptiert. Positive Tests gingen meist mit Verhaltensänderungen einher.
Fragestellung
Wie gut sind Durchführbarkeit, Akzeptanz und Wirksamkeit einer perinatalen XTS-Intervention zur Reduktion von Xylazine-Exposition und damit verbundenen Schäden?
Methode
Pilotstudie bei schwangeren und postpartalen Frauen mit Opioidkonsumstörung in einem Krankenhaus in West-Pennsylvania; Schulung zu Xylazine/XTS, Ausgabe von 5 XTS-Kits, 2 Monate Nachbeobachtung mit Echtzeit- und Abschlussbefragung sowie Interviews.
Ergebnisse
50 Teilnehmerinnen wurden eingeschlossen und nahmen die Schulung an. 17 Teilnehmerinnen reichten 71 Echtzeitbefragungen ein; in den meisten Fällen führte ein positives Ergebnis zu einer Verhaltensänderung.
Schlussfolgerung der Autor:innen
Die Autor:innen sehen Perinatal XTS als gut durchführbar und akzeptiert; die Intervention habe das Potenzial, risikobezogenes Verhalten zu verringern.
Kernaussagen
- 50 Teilnehmerinnen nahmen teil und erhielten XTS-Kits
- 71 Echtzeitbefragungen nach XTS-Nutzung wurden eingereicht
- Positive Ergebnisse führten meist zu Verhaltensänderungen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Pregnancy, online erschienen am 22.03.2026. Verfasst von Ilana Hull und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NCATS NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
The emergence of xylazine, a veterinary alpha‐2 and kappa opioid receptor agonist, as an adulterant in illicitly manufactured fentanyl has created new challenges and risks for pregnant people who use unregulated opioids. Xylazine test strips (XTSs) have been proposed as a harm reduction strategy, but their use has not been studied among pregnant and postpartum populations. The goals of this study were to assess the feasibility, acceptability, and efficacy of a novel Perinatal XTS intervention aimed at reducing xylazine exposure and associated harms.
Methods
Pregnant and postpartum women with opioid use disorder and high risk of ongoing unregulated opioid use were recruited from inpatient units of a high‐volume maternity hospital in western Pennsylvania. Participants engaged in a standardized educational session about xylazine and XTS and then were given five XTS kits. Over a 2‐month period, participants were asked to complete a real‐time survey when they used an XTS to report test results and any associated drug use behavior change. All participants were asked to participate in an end‐of‐study survey and a semi‐structured interview about their experiences with Perinatal XTS.
Results
A total of 50 participants were enrolled, completed the education session, and accepted the XTS kits. Most participants were concerned about the potential impacts of xylazine on pregnancy and neonatal outcomes. Seventeen participants submitted a total of 71 real‐time surveys after using XTS to test drug samples. In the majority of cases, a positive result prompted behavioral change. Qualitative interviews with participants revealed six major themes: (1) Xylazine and XTS education was highly acceptable. (2) Desire for additional education related to xylazine. (3) XTS distribution and use were highly acceptable. (4) Impact of XTS on behavior change varied based on participant circumstances. (5) Concerns related to xylazine's impact on maternal health and treatment. (6) Concerns related to xylazine's impact on fetal and neonatal health.
Conclusion
Findings from this pilot study demonstrate that Perinatal XTS, a harm‐reduction intervention combining xylazine and XTS education and XTS kit distribution, is highly feasible to deliver, is acceptable among pregnant and postpartum women cared for in an obstetric healthcare setting, and has the potential to reduce risk‐related behaviors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Internal Medicine Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA.
- Magee-Womens Research Institute and Foundation Pittsburgh Pennsylvania USA.
- Department of Obstetrics Gynecology & Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.
- Present address: Duquesne University, School of Nursing Pittsburgh Pennsylvania USA.
- Center for Research on Healthcare University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.
ORCID-Profile: Ilana Hull, Margaret Shang, Elizabeth Krans, Lauren Narbey, Raagini Jawa
Förderung
- NIDA NIH HHS
- NCATS NIH HHS
Zitieren
APA
Hull, I., Shang, M., Krans, E., Stewart, E., Ritter, M., Narbey, L., Mayo, S., & Jawa, R. (2026). Xylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study. Pregnancy, 2(2). https://doi.org/10.1002/pmf2.70274
Vancouver
Hull I, Shang M, Krans E, Stewart E, Ritter M, Narbey L, et al. Xylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study. Pregnancy. 2026;2(2). doi:10.1002/pmf2.70274
BibTeX
@article{Hull2026,
author = {Hull, Ilana and Shang, Margaret and Krans, Elizabeth and Stewart, Ellen and Ritter, Megan and Narbey, Lauren and Mayo, Samantha and Jawa, Raagini},
title = {Xylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study},
journal = {Pregnancy},
year = {2026},
volume = {2},
number = {2},
doi = {10.1002/pmf2.70274}
}
EUVIMED